Sionna Therapeutics, Inc. Return Tang Equity
Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
- Sionna Therapeutics, Inc. return tang equity for the quarter ending 2026-06-30 was -36.64%, a change of -14.10% year-over-year.
- Sionna Therapeutics, Inc. return tang equity for the quarter ending 2026-03-31 was -29.69%, a change of -10.83% year-over-year.
- Sionna Therapeutics, Inc. return tang equity for the quarter ending 2025-12-31 was -24.53%, a 165.10% decline year-over-year.
- Sionna Therapeutics, Inc. return tang equity for the quarter ending 2025-09-30 was -21.97%.
- Sionna Therapeutics, Inc. return tang equity for fiscal 2025 was -24.53%, a 165.10% decline from fiscal 2024.
- Sionna Therapeutics, Inc. return tang equity for fiscal 2024 was 37.68%.
- Available history
- 2024-12-31 to 2026-06-30
- Data captured
Historical Return Tang Equity
Annual Return Tang Equity
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |